According to a trial conducted in Burkina Faso in 2019, the vaccine developed by Oxford University showed 77% effectiveness.
It was announced on Friday (April 23) that the candidate malaria vaccine has shown unparalleled efficacy in African trials, reaching 77%, which gives people hope for a major breakthrough in the fight against the disease that mainly kills children.
The university cooperating with Novavax in the United States said that the vaccine R21/Matrix-M is the first vaccine to reach the 75% efficacy target set by the World Health Organization (WHO). Published in the scientific journal “The Lancet”, “These new results give great hope to the potential of this vaccine”Professor Adrian Hill, director of the Jenner Institute at the University of Oxford, commented in the press release that he is also behind the anti-Covid vaccine jointly developed by AstraZeneca and AstraZeneca.
The serum can be approved within two years and is synonymous with hope for the fear of malaria resistance to treatment. This mosquito-borne parasitic disease killed more than 400,000 people worldwide in 2019, including two-thirds of children under five. According to the World Health Organization, the vast majority of cases (94% of the 229 million infections worldwide) and deaths occurred in Africa.
According to a 2019 phase II trial of 450 Burkina Faso children aged 5 to 17 months, the Oxford University vaccine showed 77% efficacy in people who received high-dose adjuvants, while those receiving low-dose adjuvants It showed 71% efficacy in the population of the drug. No serious side effects were observed. 4800 children have been recruited in four African countries/regions to enter the final stages of clinical trials.
The vaccine designer pointed out that this vaccine can be produced on a large scale and at low cost. A partnership has been established with the Serum Institute of India (SII), which has produced the anti-Covid vaccine Oxford/AstraZeneca, “At least 200 million annual doses will be produced in the next few years”According to Adrian Hill.
As part of a pilot program initiated by the World Health Organization, another vaccine developed by the British giant GlaxoSmithKline (GSK) has been vaccinated to approximately 650,000 children in Malawi, Ghana and Kenya since 2019 . Facts have proved that this method is less effective and can prevent four out of ten malaria and three out of ten serious life-threatening malaria.